MetaCap

Prime Medicine Inc. (PRME)

NASDAQ: PRMEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

3.55-0.29 (-7.55%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PRME stock chart

Technical analysis

Key statistics

All statistics
Market cap
$791.62M
EPS (TTM)
-$0.97
52-week range
2.67 – 5.91
Day range
3.49 – 3.93
Volume / Avg
6.13M / 4.64M
Beta
—

52-week range

$2.67$5.91

PRME stock today

On Nov 20, PRME ended the session at $3.55, shedding $0.29 (7.55%), versus the S&P 500's 3.70% decline. At this level, PRME sits in the middle of its 52-week range of $2.67 to $5.91: 39.9% below the high, set on Oct 29, 2026 and 33.0% above the low. PRME is up 2.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 2.2%.

Prime Medicine has posted a net loss over the last twelve months (EPS of -$0.97), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Prime Medicine

Company profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Allan Reine M.D.
Headquarters
Cambridge, MA
Employees
146
IPO year
2022

Financial highlights

Full financials

In fiscal 2025, Prime Medicine generated $4.6 million in revenue, up 55.3% from fiscal 2024, its 2nd consecutive year of revenue growth. Prime Medicine reported a net loss of $201.1 million, compared with a loss of $195.9 million a year earlier. Operating margin was -4498.1%.

Prime Medicine annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$4.63M$2.98M$0$0$0
Growth+55.28%———-100.00%
Net income$-201.14M$-195.88M$-198.13M$-121.82M$-165.37M
EPS (diluted)$-1.35$-1.65$-2.18$-4.19$-14.19

Analyst forecast

Forecast

Consensus (13 analysts)

buy

Avg. price target

$7.39+108.17%

  • Strong buy 1
  • Buy 9
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $4.25High $11.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.22 vs $-0.23
Surprise
+4.35%

PRME news

All PRME news

Prime Medicine peers

Health Care sector
PRME peer companies
CompanyPrice% ChgMarket capCompare
MGTXMeiraGTx Holdings plc7.98-1.97%$779.89Mvs PRME
BBTXBambusa Therapeutics Inc.16.00+2.89%$815.08Mvs PRME
ODTXOdyssey Therapeutics Inc.16.96-7.52%$815.23Mvs PRME
GLUEMonte Rosa Therapeutics Inc.8.64-3.03%$738.29Mvs PRME
AURAAura Biosciences Inc.6.87-1.58%$714.99Mvs PRME
IMTXImmatics N.V.5.77-3.03%$878.58Mvs PRME
SLDBSolid Biosciences Inc.6.25-2.95%$697.57Mvs PRME
ATTOAttovia Therapeutics Inc.15.10-3.08%$690.26Mvs PRME

Indexes, lists and sector

Prime Medicine stock FAQ

What is Prime Medicine's stock price today?

PRME last traded at $3.55 as of Nov 20, 4:00 PM EST, down 7.55% on the day. Prices are delayed at least 15 minutes.

Who is Prime Medicine's CEO?

Dr. Allan Reine M.D. is the chief executive officer of Prime Medicine Inc., which has about 146 employees.

What is the PRME 52-week high?

The 52-week high for PRME is $5.91 and the 52-week low is $2.67. The stock is currently 39.9% below its high.

Compare PRME